Literature DB >> 20042512

Relationship between antibody 2F5 neutralization of HIV-1 and hydrophobicity of its heavy chain third complementarity-determining region.

Gilad Ofek1, Krisha McKee, Yongping Yang, Zhi-Yong Yang, Jeff Skinner, F Javier Guenaga, Richard Wyatt, Michael B Zwick, Gary J Nabel, John R Mascola, Peter D Kwong.   

Abstract

The membrane-proximal external region (MPER) of the HIV-1 gp41 transmembrane glycoprotein is the target of the broadly neutralizing antibody 2F5. Prior studies have suggested a two-component mechanism for 2F5-mediated neutralization involving both structure-specific recognition of a gp41 protein epitope and nonspecific interaction with the viral lipid membrane. Here, we mutationally alter a hydrophobic patch on the third complementarity-determining region of the heavy chain (CDR H3) of the 2F5 antibody and assess the abilities of altered 2F5 variants to bind gp41 and to neutralize diverse strains of HIV-1. CDR H3 alterations had little effect on the affinity of 2F5 variants for a peptide corresponding to its gp41 epitope. In contrast, strong effects and a high degree of correlation (P < 0.0001) were found between virus neutralization and CDR H3 hydrophobicity, as defined by predicted free energies of transfer from water to a lipid bilayer interface or to octanol. The effect of CDR H3 hydrophobicity on neutralization was independent of isolate sensitivity to 2F5, and CDR H3 variants with tryptophan substitutions were able to neutralize HIV-1 approximately 10-fold more potently than unmodified 2F5. A threshold was observed for increased hydrophobicity of the 2F5 CDR H3 loop beyond which effects on 2F5-mediated neutralization leveled off. Together, the results provide a more complete understanding of the 2F5 mechanism of HIV-1 neutralization and indicate ways to enhance the potency of MPER-directed antibodies.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20042512      PMCID: PMC2826063          DOI: 10.1128/JVI.02257-09

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  47 in total

1.  4E10 and 2F5 monoclonal antibodies: binding specificities to phospholipids, tolerance, and clinical safety issues.

Authors:  Carl R Alving
Journal:  AIDS       Date:  2008-03-12       Impact factor: 4.177

2.  Broad HIV-1 neutralization mediated by CD4-binding site antibodies.

Authors:  Yuxing Li; Stephen A Migueles; Brent Welcher; Krisha Svehla; Adhuna Phogat; Mark K Louder; Xueling Wu; George M Shaw; Mark Connors; Richard T Wyatt; John R Mascola
Journal:  Nat Med       Date:  2007-08-26       Impact factor: 53.440

3.  Structural details of HIV-1 recognition by the broadly neutralizing monoclonal antibody 2F5: epitope conformation, antigen-recognition loop mobility, and anion-binding site.

Authors:  Jean-Philippe Julien; Steve Bryson; Jose L Nieva; Emil F Pai
Journal:  J Mol Biol       Date:  2008-09-18       Impact factor: 5.469

4.  MPEx: a tool for exploring membrane proteins.

Authors:  Craig Snider; Sajith Jayasinghe; Kalina Hristova; Stephen H White
Journal:  Protein Sci       Date:  2009-12       Impact factor: 6.725

5.  The role of antibody polyspecificity and lipid reactivity in binding of broadly neutralizing anti-HIV-1 envelope human monoclonal antibodies 2F5 and 4E10 to glycoprotein 41 membrane proximal envelope epitopes.

Authors:  S Munir Alam; Mildred McAdams; David Boren; Michael Rak; Richard M Scearce; Feng Gao; Zenaido T Camacho; Daniel Gewirth; Garnett Kelsoe; Pojen Chen; Barton F Haynes
Journal:  J Immunol       Date:  2007-04-01       Impact factor: 5.422

6.  Specific phospholipid recognition by human immunodeficiency virus type-1 neutralizing anti-gp41 2F5 antibody.

Authors:  Silvia Sánchez-Martínez; Maier Lorizate; Katinger Hermann; Renate Kunert; Gorka Basañez; José L Nieva
Journal:  FEBS Lett       Date:  2006-04-17       Impact factor: 4.124

7.  Reassessment of autoreactivity of the broadly neutralizing HIV antibodies 4E10 and 2F5 and retrospective analysis of clinical safety data.

Authors:  Brigitta Vcelar; Gabriela Stiegler; Hermann M Wolf; Wolfgang Muntean; Bettina Leschnik; Saurabh Mehandru; Martin Markowitz; Christine Armbruster; Renate Kunert; Martha M Eibl; Hermann Katinger
Journal:  AIDS       Date:  2007-10-18       Impact factor: 4.177

8.  Difficulties in eliciting broadly neutralizing anti-HIV antibodies are not explained by cardiolipin autoreactivity.

Authors:  Erin M Scherer; Michael B Zwick; Luc Teyton; Dennis R Burton
Journal:  AIDS       Date:  2007-10-18       Impact factor: 4.177

9.  HIV-1 broadly neutralizing antibody extracts its epitope from a kinked gp41 ectodomain region on the viral membrane.

Authors:  Zhen-Yu J Sun; Kyoung Joon Oh; Mikyung Kim; Jessica Yu; Vladimir Brusic; Likai Song; Zhisong Qiao; Jia-huai Wang; Gerhard Wagner; Ellis L Reinherz
Journal:  Immunity       Date:  2008-01       Impact factor: 31.745

10.  Structural definition of a conserved neutralization epitope on HIV-1 gp120.

Authors:  Tongqing Zhou; Ling Xu; Barna Dey; Ann J Hessell; Donald Van Ryk; Shi-Hua Xiang; Xinzhen Yang; Mei-Yun Zhang; Michael B Zwick; James Arthos; Dennis R Burton; Dimiter S Dimitrov; Joseph Sodroski; Richard Wyatt; Gary J Nabel; Peter D Kwong
Journal:  Nature       Date:  2007-02-15       Impact factor: 49.962

View more
  68 in total

1.  Crystal structure of PG16 and chimeric dissection with somatically related PG9: structure-function analysis of two quaternary-specific antibodies that effectively neutralize HIV-1.

Authors:  Marie Pancera; Jason S McLellan; Xueling Wu; Jiang Zhu; Anita Changela; Stephen D Schmidt; Yongping Yang; Tongqing Zhou; Sanjay Phogat; John R Mascola; Peter D Kwong
Journal:  J Virol       Date:  2010-06-10       Impact factor: 5.103

2.  Enhanced HIV-1 neutralization by antibody heteroligation.

Authors:  Hugo Mouquet; Malte Warncke; Johannes F Scheid; Michael S Seaman; Michel C Nussenzweig
Journal:  Proc Natl Acad Sci U S A       Date:  2012-01-04       Impact factor: 11.205

Review 3.  Rational design of vaccines to elicit broadly neutralizing antibodies to HIV-1.

Authors:  Peter D Kwong; John R Mascola; Gary J Nabel
Journal:  Cold Spring Harb Perspect Med       Date:  2011-09       Impact factor: 6.915

4.  Scaffolding to build a rational vaccine design strategy.

Authors:  Dennis R Burton
Journal:  Proc Natl Acad Sci U S A       Date:  2010-10-11       Impact factor: 11.205

5.  Elicitation of structure-specific antibodies by epitope scaffolds.

Authors:  Gilad Ofek; F Javier Guenaga; William R Schief; Jeff Skinner; David Baker; Richard Wyatt; Peter D Kwong
Journal:  Proc Natl Acad Sci U S A       Date:  2010-09-27       Impact factor: 11.205

6.  Crystal structure of a non-neutralizing antibody to the HIV-1 gp41 membrane-proximal external region.

Authors:  Nathan I Nicely; S Moses Dennison; Leonard Spicer; Richard M Scearce; Garnett Kelsoe; Yoshihiro Ueda; Haiyan Chen; Hua-Xin Liao; S Munir Alam; Barton F Haynes
Journal:  Nat Struct Mol Biol       Date:  2010-11-14       Impact factor: 15.369

7.  Antibody mechanics on a membrane-bound HIV segment essential for GP41-targeted viral neutralization.

Authors:  Mikyung Kim; Zhen-Yu J Sun; Kasper D Rand; Xiaomeng Shi; Likai Song; Yuxing Cheng; Amr F Fahmy; Shreoshi Majumdar; Gilad Ofek; Yongping Yang; Peter D Kwong; Jia-Huai Wang; John R Engen; Gerhard Wagner; Ellis L Reinherz
Journal:  Nat Struct Mol Biol       Date:  2011-10-16       Impact factor: 15.369

8.  HIV-1 gp140 epitope recognition is influenced by immunoglobulin DH gene segment sequence.

Authors:  Yuge Wang; Pratibha Kapoor; Robert Parks; Aaron Silva-Sanchez; S Munir Alam; Laurent Verkoczy; Hua-Xin Liao; Yingxin Zhuang; Peter Burrows; Michael Levinson; Ada Elgavish; Xiangqin Cui; Barton F Haynes; Harry Schroeder
Journal:  Immunogenetics       Date:  2015-12-19       Impact factor: 2.846

9.  Antigenic properties of the HIV envelope on virions in solution.

Authors:  Krishanu Ray; Meron Mengistu; Lei Yu; George K Lewis; Joseph R Lakowicz; Anthony L DeVico
Journal:  J Virol       Date:  2013-11-27       Impact factor: 5.103

10.  In-solution virus capture assay helps deconstruct heterogeneous antibody recognition of human immunodeficiency virus type 1.

Authors:  Daniel P Leaman; Heather Kinkead; Michael B Zwick
Journal:  J Virol       Date:  2010-01-20       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.